scholarly journals High‐normal urinary albumin‐to‐creatinine ratio is independently associated with metabolic syndrome in C hinese patients with type 2 diabetes mellitus: A cross‐sectional community‐based study

2014 ◽  
Vol 6 (3) ◽  
pp. 354-359 ◽  
Author(s):  
Mei‐Fang Li ◽  
Qi‐Ming Feng ◽  
Lian‐Xi Li ◽  
Yin‐Fang Tu ◽  
Rong Zhang ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Urinary Albumin ◽  
Creatinine Ratio ◽  
Community Based ◽  
Cross Sectional

scholarly journals Prevalence of Metabolic Syndrome in individuals with Type 2 Diabetes Mellitus

2017 ◽  
Vol 70 (2) ◽  
pp. 265-270 ◽  
Author(s):  
José Cláudio Garcia Lira Neto ◽  
Mayra de Almeida Xavier ◽  
José Wicto Pereira Borges ◽  
Márcio Flávio Moura de Araújo ◽  
Marta Maria Coelho Damasceno ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Descriptive Analysis ◽  
Cross Sectional Study ◽  
Diabetic Patients ◽  
Chi Square ◽  
Cross Sectional

ABSTRACT Objective: to identify the prevalence of Metabolic Syndrome and its components in a population of patients with type 2 Diabetes Mellitus. Method: a cross-sectional study was conducted with 201 diabetic patients. A descriptive analysis and Chi-square and Fisher's exact tests ( p <0.05) were performed. Results: the majority of participants were females and overweight, with a mean age of 63.1 years and a low level of education, and categorized as physically inactive. Of all individuals investigated, 50.7% were diagnosed with Metabolic Syndrome and 92% had at least one of the syndrome components with values beyond those recommended. Conclusion: it is essential to take preventive actions and develop studies that help to identify the factors associated with this syndrome.

Postprandial serum C-peptide level is associated with increased urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus

2017 ◽  
Vol 87 (06) ◽  
pp. 320-322
Author(s):  
Eijiro Yamada ◽  
Tsugumichi Saito ◽  
Yawara Niijima ◽  
Shuichi Okada ◽  
Masanobu Yamada
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Urinary Albumin ◽  
Creatinine Ratio ◽  
C Peptide ◽  
Peptide Level

scholarly journals Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria

2019 ◽  
Vol 14 (8) ◽  
pp. 1161-1172 ◽  
Author(s):  
Sadayoshi Ito ◽  
Kenichi Shikata ◽  
Masaomi Nangaku ◽  
Yasuyuki Okuda ◽  
Tomoko Sawanobori
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Adverse Events ◽  
Renin Angiotensin System ◽  
Urinary Albumin ◽  
Creatinine Ratio ◽  
Angiotensin System ◽  
Renin Angiotensin

Background and objectivesThe progression of kidney disease in some patients with type 2 diabetes mellitus may not be adequately suppressed by renin-angiotensin system inhibitors. Esaxerenone (CS-3150) is a nonsteroidal mineralocorticoid receptor blocker that has shown kidney protective effects in preclinical studies, and it is a potential add-on therapy to treat diabetic kidney disease. This phase 2 study evaluated the efficacy and safety of esaxerenone in Japanese patients with type 2 diabetes mellitus and microalbuminuria.Design, setting, participants, & measurementsThis multicenter, randomized, double-blind, placebo-controlled trial enrolled 365 hypertensive or normotensive patients with type 2 diabetes mellitus and microalbuminuria (urinary albumin-to-creatinine ratio ≥45 to <300 mg/g creatinine) treated with renin-angiotensin system inhibitor who had eGFR≥30 ml/min per 1.73 m2. Participants were randomized to receive 0.625, 1.25, 2.5, or 5 mg/d esaxerenone or placebo for 12 weeks. The primary end point was the change in urinary albumin-to-creatinine ratio from baseline to week 12 (with last observation carried forward).ResultsEsaxerenone treatment at 1.25, 2.5, and 5 mg/d significantly reduced urinary albumin-to-creatinine ratio by the end of treatment (38%, 50%, and 56%, respectively) compared with placebo (7%; all P<0.001). The urinary albumin-to-creatinine ratio remission rate (defined as urinary albumin-to-creatinine ratio <30 mg/g creatinine at the end of treatment and ≥30% decrease from baseline) was 21% in the 2.5- and 5-mg/d groups versus 3% for placebo (both P<0.05). Adverse events occurred slightly more frequently with esaxerenone versus placebo, but the frequencies of drug-related adverse events and discontinuation rates were similar in the placebo and the 0.625-, 1.25-, and 2.5-mg/d groups. Drug-related adverse events and treatment discontinuations were marginally higher in the 5-mg/d group. The most common drug-related adverse event was hyperkalemia, which was dose proportional.ConclusionsAdding esaxerenone at 1.25, 2.5, and 5 mg/d for 12 weeks to an ongoing renin-angiotensin system inhibitor significantly reduces urinary albumin-to-creatinine ratio in patients with type 2 diabetes mellitus and microalbuminuria.

scholarly journals Prevalence of Metabolic Syndrome and Its Components in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study at a Tertiary Care Teaching Hospital

2019 ◽  
Vol 9 (2) ◽  
pp. 24-29
Author(s):  
Santosh Timalsina ◽  
Pratima Pandit
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Metabolic Syndrome ◽  
Type 2 Diabetes Mellitus ◽  
Teaching Hospital ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional

Introduction: The metabolic syndrome (MetS) is a cluster of risk fac­tors that is responsible for most of the excess cardiovascular morbidity amongst patients with Type 2 Diabetes Mellitus (T2DM). Presence of MetS in T2DM markedly increases the risk for coronary heart disease, stroke and premature deaths. This study was undertaken to find the prevalence of MetS and its individual components among patients with T2DM visiting Chitwan Medical College and Teaching Hospital, Bharat­pur, Nepal. Methods: A laboratory-based descriptive cross sectional study carried out at CMC-TH between January and August, 2017. Data obtained in­cluded anthropometric indices, blood pressure and fasting serum lipid profile. National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria were used for diagnosis of MetS. Data was ana­lyzed using SPSS version 20. Results: The overall prevalence of MetS among 150 T2DM patients (Mean age= 53.70±10.83 years, Male:Female=84:66) was 60%. The prev­alence was higher in females compared to males (75.75% vs.47.62%, P<0.001). High blood pressure was the commonest MetS component. Following that, decreased HDL-c was the predominant component in females whereas raised triglyceride in the males. SBP/DBP, BMI and waist circumference were significantly associated with MetS. Conclusion: The prevalence of MetS is high in diabetic patients, particu­larly in females and middle age group adults, with high blood pressure and hypertriglyceridemia as the commonest abnormalities. As MetS adds to the cardiovascular risk to the already at-risk diabetic popula­tion, timely identification and appropriate intervention is of utmost im­portance in reduction of disease burden in T2DM patients.

Sign in / Sign up

Export Citation Format

Share Document